Lupin, a Rs. 22,700 crore plus Mumbai based pharma major has posted strong financial performance during the second quarter ended September 2025 with significant jump in revenues from US and emerging markets. Its consolidated net profit went up by 72.8 per cent to Rs. 1,484 crore from Rs. 859 crore in the corresponding period of last year. EBITDA also jump by 76 per cent to Rs. 2,431 crore from Rs. 1,383 crore. Its revenues increased by 24.2 per cent to Rs. 7,048 crore from Rs. 5,673 crore. EPS, for the face value of Re.1 per share, improved to Rs. 32.36 from Rs. 18.70 in the last period.
Nilesh Gupta, managing director, said “We are delighted to present one of our strongest performances ever in this second quarter of FY26. We continue to see robust growth in revenues and EBITDA led by strong performance across the board, in the US, emerging markets, other developed markets and in India, supported by higher operational efficiencies and sustained investments. We intend to leverage the performance of H1 to deliver a strong FY26.”
Lupin’s total formulation sales moved up by 26.4 per cent to Rs. 6,575 crore from Rs. 5,203 crore. However, APIs sales declined by 12.6 per cent to Rs. 257 crore as against Rs. 294 crore. The company’s US formulation sales increased by 47.3 per cent to Rs. 2,762 crore from Rs. 1,875 crore in the similar quarter of last year. The company now has 147 generic products in the US market. US sales contributed 40 per cent to its global revenue. Its Indian formulation sales increased only by 3.3 per cent to Rs. 2,077 crore from Rs. 2,010 crore and contributed 30 per cent in its total sales. It launched 6 brands across therapies in India during the quarter.
Lupin’s research and development expenditure went up by 13.6 per cent to Rs. 509 crore (7.5% of sales) for the quarter as compared to Rs. 448 crore (8.2% of sales) for Q2 FY2025. Lupin received approval for 6 ANDAs from the US FDA in the quarter. Cumulative ANDA filings with the US FDA stand at 433 as of September 30, 2025, with the company having received 341 approvals to date. The company now has 50 First-to-File (FTF) filings including 20 exclusive FTF opportunities. Cumulative US DMF filings stand at 91 as of September 30, 2025.
Lupin and its subsidiary, agreed to settle the dispute for an amount of USD 9.0 million in connection with the drugs Glumetza without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation.
For the first half, Lupin registered revenue growth of 18.1 per cent to Rs. 13,316 crore from Rs. 11,273 crore in the same period of last year. Its other income increased to Rs. 169 crore from Rs 86 crore. Its net profit has taken quantum jump of 63 per cent and touched to Rs. 2,706 crore from Rs. 1,665 crore. For the full year ended March 2025, Lupin’s revenues worked out to Rs. 22,708 crore and it registered net profit of Rs. 3,306 crore. |